ATRA Revenue Breakdown
ATRA Revenue Breakdown summary
Atara Biotherapeutics, Inc. (ATRA). Quarter ended 2026-06-30 · 10-Q · every retained filed quarter remains available.
- 2025-12-31: Others Not split by product in the filing$120.77M100.00%; Total revenue $120.77M.
- 2024-12-31: Others Not split by product in the filing$128.94M100.00%; Total revenue $128.94M.
- 2023-12-31: Others Not split by product in the filing$8.57M100.00%; Total revenue $8.57M.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $120.77M 100.00% | $120.77M |
| 2024-12-31 | Not split by product in the filing $128.94M 100.00% | $128.94M |
| 2023-12-31 | Not split by product in the filing $8.57M 100.00% | $8.57M |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $630.00K 100.00% | $630.00K |
| 2026-03-31 | Not split by product $516.00K 100.00% | $516.00K |
| 2025-12-31 | Not split by product $1.59M 100.00% | $1.59M |
| 2025-09-30 | Not split by product $3.45M 100.00% | $3.45M |
| 2025-06-30 | Not split by product $17.57M 100.00% | $17.57M |
| 2025-03-31 | Not split by product $98.15M 100.00% | $98.15M |
| 2024-12-31 | Not split by product $32.75M 100.00% | $32.75M |
| 2024-09-30 | Not split by product $40.19M 100.00% | $40.19M |
| 2024-06-30 | Not split by product $28.64M 100.00% | $28.64M |
| 2024-03-31 | Not split by product $27.36M 100.00% | $27.36M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |